Condition

Head & Neck Squamous Cell Carcinoma clinical trials and research

• 7Clinical trials
• 5Countries

Newest Head & Neck Squamous Cell Carcinoma clinical trials

All recruiting trials (7)

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Adaptive daily replanning of radiotherapy for head and neck cancer.

  This tests whether doing same-day replanning of radiotherapy each treatment can reduce side effects for people receiving curative radiotherapy for head and neck squamous cell carcinoma.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT07506902

• Postbiotix-HLA™ with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.

  This trial will test whether taking the postbiotic supplement Postbiotix-HLA™ with first-line pembrolizumab reduces immune-related side effects and alters microbiota in people with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting Phase 2 Gruppo Oncologico del Nord-Ovest · Rozzano, Milano · NCT07485296

• Early PET/CT response after first‑line pembrolizumab in recurrent or metastatic head and neck cancer

  This project will see if an 18F‑FDG PET/CT scan after two doses of pembrolizumab can tell who is responding among patients with recurrent or metastatic PD‑L1 CPS ≥1 head and neck cancer.

  Recruiting University of Rome Tor Vergata · Rome, Italy · NCT07448727

• Postoperative radiotherapy with nimotuzumab followed by bemcentinib for high-risk head and neck cancer patients who can't take cisplatin

  This study will see if adding nimotuzumab during postoperative radiotherapy followed by bemcentinib can help prevent recurrence in high-risk head and neck cancer patients who are unable to receive cisplatin.

  Recruiting Phase 3 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT07445048

• 4D dynamic LAFOV FDG-PET to tell leftover cancer from post-radiation inflammation in head and neck squamous cell carcinoma

  This study will test whether a 4D dynamic long‑axial‑field‑of‑view FDG‑PET scan can tell remaining head and neck squamous cell cancer from normal post‑radiation inflammation in adults about three months after finishing curative radiotherapy.

  Recruiting University Hospital, Brest · Brest and 2 other locations · NCT07417605

• Radiotherapy with nimotuzumab versus radiotherapy alone for platinum-ineligible advanced head and neck squamous cell carcinoma

  This trial tests whether adding nimotuzumab to radiotherapy helps people with advanced head and neck squamous cell carcinoma who cannot receive platinum chemotherapy.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Shandong, Province · NCT07333274

Related topics

Quick answers

How many Head & Neck Squamous Cell Carcinoma clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (2 trials), Italy (2 trials), Denmark (1 trial), United States (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 2, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →